Rigel Pharmaceuticals Inc Stock Price, News & Analysis

Rigel Pharmaceuticals (NASDAQ: RIGL) announced seven upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress, showcasing data for GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib). Key highlights include:

For GAVRETO in RET fusion-positive NSCLC:

• Overall response rate: 70.3%
• Median duration of response: 19.1 months
• Median overall survival: 44.3 months
• Median progression-free survival: 13.1 months

For REZLIDHIA in mIDH1 R/R AML:

• Higher response rates in patients with 1-2 prior regimens vs ≥3 prior therapies
• 50% overall response rate in primary refractory patients
• Demonstrated efficacy across IDH1-R132 mutation types

The presentations will take place at ASCO (May 30-June 3, 2025) in Chicago and EHA (June 12-15, 2025) in Milan.

Rigel Pharmaceuticals (RIGL) reported strong Q1 2025 financial results with total revenue of $53.3 million, including $43.6 million in net product sales (68% YoY growth) and $9.8 million in contract revenues. The company generated $11.4 million in net income, compared to a loss in Q1 2024. Product sales were driven by TAVALISSE ($28.5M), GAVRETO ($9.0M), and REZLIDHIA ($6.1M). R289 received Orphan Drug and Fast Track designations for MDS treatment. The company maintains its 2025 outlook of $200-210 million in total revenue and expects positive net income for the full year. Additionally, Rigel anticipates recognizing $40 million in non-cash revenue in Q2 2025 related to its Lilly collaboration.

Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its first quarter 2025 financial results announcement and business update for Tuesday, May 6, 2025, after market close. The company will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Investors can join the call through two options:

• Phone: 877-407-3088 (domestic) or 201-389-0927 (international)
• Webcast: Available through the Investor Relations section at www.rigel.com

Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer. The webcast will be archived and accessible for replay through the company website for 90 days following the call.

Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 23,350 stock options and restricted stock units awarded to seven non-executive employees.

These equity awards will vest over a four-year period with a one-year cliff vesting schedule. The grants serve as inducement material for employees entering into employment with Rigel, a biotechnology company founded in 1996 that focuses on developing therapies for hematologic disorders and cancer.

Rigel Pharmaceuticals (Nasdaq: RIGL) has reached a settlement agreement with Annora Pharma and Hetero Labs regarding patent litigation for its drug TAVALISSE® (fostamatinib disodium hexahydrate). The litigation arose from Annora's submission of an Abbreviated New Drug Application to the FDA for a generic version of TAVALISSE.

Under the settlement terms, Annora will receive a license to sell its generic product in Q2 2032 or earlier under certain circumstances. All ongoing litigation between the parties regarding TAVALISSE patents pending in New Jersey has been terminated. TAVALISSE is indicated for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich brings over 25 years of experience in developing cellular immunotherapies for cancer treatment, with expertise in clinical drug development and translational research.

Currently serving as CEO of Indapta Therapeutics, Dr. Frohlich previously led portfolio strategy at Juno Therapeutics and served as CMO at Dendreon , where he led the development and regulatory approval of PROVENGE®. His background includes positions at UCSF as an assistant adjunct professor of hematology/oncology, with degrees from Yale College and Harvard Medical School.

Dr. Frohlich will contribute to advancing Rigel's hematology and oncology pipeline, particularly focusing on the IRAK1/4 and IDH1 inhibitor programs for lower-risk myelodysplastic syndrome and glioma treatments respectively.

Rigel Pharmaceuticals (RIGL) reported strong financial results for Q4 and full year 2024. Q4 total revenue reached $57.6 million, including TAVALISSE sales of $31.0M, REZLIDHIA sales of $7.4M, and GAVRETO sales of $8.1M.

Full year 2024 revenue totaled $179.3 million, with TAVALISSE sales at $104.8M (12% growth), REZLIDHIA at $23.0M (118% growth), and GAVRETO at $17.1M. The company achieved its first full-year net income of $17.5 million, with cash reserves increasing by over $20M.

Notable developments include R289 receiving FDA Fast Track designation for treating previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for MDS treatment. For 2025, Rigel projects total revenue of $200-210 million, including net product sales of $185-192M and contract revenues of $15-18M, expecting continued profitability.

Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 4, 2025, after market close. The announcement will be followed by a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), where senior management will discuss financial results and provide a business update.

Participants can join the conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The call and accompanying slides will also be webcast live from the Investor Relations section of Rigel's website and archived for 90 days afterward.

Rigel Pharmaceuticals is a biotechnology company founded in 1996 that focuses on discovering, developing, and providing novel therapies for patients with hematologic disorders and cancer. The company is headquartered in South San Francisco, California.

Rigel Pharmaceuticals (NASDAQ: RIGL) announced the enrollment of the first patient in a NIH/NHLBI-sponsored Phase 1 study evaluating fostamatinib in sickle cell disease (SCD) patients. The study will assess the safety and tolerability of escalating doses of fostamatinib, Rigel's oral SYK inhibitor, which is already approved as TAVALISSE® for chronic immune thrombocytopenia.

The open-label Phase 1 dose-escalation study aims to enroll approximately 20 patients with SCD. Patients will receive 100 mg twice daily for 14 days, potentially escalating to 150 mg twice daily for an additional 28 days if tolerated. The study will evaluate safety, tolerability, and investigate fostamatinib's mechanism of action in SCD, including its effects on red blood cell membrane integrity, sickling kinetics, and platelet activation.

The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland, with study material provided by Rigel. SCD affects over 100,000 people in the United States and an estimated 7-8 million people worldwide.